Connecticut Bill Would Require Emergency Departments to Offer Buprenorphine for Opioid Use Disorder

Connecticut lawmakers are considering legislation that would fundamentally change how emergency departments across the state respond to patients experiencing opioid use disorder. Senate Bill 365, currently under review by the Office of Legislative Research and Office of Fiscal Analysis following a public hearing earlier this month, would require all emergency departments to offer buprenorphine—a highly effective medication for treating opioid addiction—to patients presenting with opioid use disorder symptoms.

The proposal arrives as Connecticut continues grappling with an opioid crisis that has claimed thousands of lives over the past decade. Unlike many policy interventions that focus on prevention or criminal justice reform, SB 365 targets a critical intervention point: the moment when someone struggling with addiction seeks help at an emergency department, often following an overdose or during acute withdrawal.

The Evidence Behind the Mandate

The scientific case for emergency department-initiated buprenorphine has grown increasingly robust over the past several years. A landmark 2020 study published in JAMA Network Open found that patients treated with buprenorphine or methadone experienced a 76% reduction in overdose risk at three months compared to those who received no medication-assisted treatment. The protective effect extends beyond immediate overdose prevention—the same research documented a 32% reduction in opioid-related emergency department visits among patients prescribed these medications.

Connecticut-specific research adds urgency to the legislative push. A Yale University study published in 2023 found that attempting to treat opioid use disorder without medications like buprenorphine or methadone is actually more dangerous than providing no treatment at all, associated with a 77% higher risk of fatal opioid overdose. The finding underscores what addiction medicine specialists have long argued: abstinence-only approaches to opioid addiction can be counterproductive and even deadly.

Dr. Cara Borelli, an addiction medicine physician who works in New Haven and co-editor-in-chief of the Journal of Child and Adolescent Substance Use, wrote in support of SB 365 that the mortality risk for patients who receive naloxone (the overdose reversal medication) is higher at one year than for those who experience a life-threatening heart attack. "An ER doctor would never fail to treat a life-threatening heart attack by treating the patient and activating the cardiology team," she noted, "yet I have repeatedly seen colleagues decide not to start buprenorphine for a patient requesting it for opioid use disorder treatment, often due to a misunderstanding of the morbidity and mortality of opioid use disorder."

How Buprenorphine Works in Emergency Settings

Buprenorphine is a partial opioid agonist, meaning it activates the same brain receptors as heroin or fentanyl but produces a weaker effect. For someone in withdrawal or at risk of overdose, a carefully dosed buprenorphine prescription can eliminate cravings and withdrawal symptoms while blocking the euphoric effects of other opioids if used. The medication doesn't produce the dangerous respiratory depression associated with full opioid agonists, making it significantly safer.

Emergency departments represent ideal settings for initiating buprenorphine treatment for several reasons. Patients often arrive during moments of crisis—following overdoses, during severe withdrawal, or when complications from injection drug use bring them to seek care. These moments of acute distress can create windows of motivation for treatment that may not persist once the immediate crisis passes. Starting buprenorphine in the ED, paired with a bridge prescription lasting until outpatient follow-up, dramatically increases the likelihood that patients will engage with ongoing treatment rather than returning to drug use upon discharge.

The proposed Connecticut legislation would require emergency departments not only to offer buprenorphine but also to provide bridge prescriptions lasting until the patient's follow-up appointment. Advocates are pushing for an amendment specifying at least seven days of medication to reduce gaps in treatment. Follow-up care could occur with addiction specialists, psychiatrists, primary care physicians, or through telehealth platforms—the key is ensuring continuity rather than discharging patients with vague referrals they may never pursue.

Hospital Opposition and Cost Considerations

Despite the evidence supporting emergency department-initiated buprenorphine, the Connecticut Hospital Association has opposed SB 365, framing it as an unfunded mandate that would increase healthcare costs. The position has frustrated addiction medicine advocates who point to substantial evidence that buprenorphine treatment reduces overall healthcare expenditures.

Insurance claims data demonstrates that patients prescribed buprenorphine incur lower outpatient charges, lower inpatient charges, and overall yearly healthcare costs more than $20,000 less per person compared to those not receiving medication-assisted treatment. The savings stem from reduced emergency department visits, fewer hospitalizations for injection-related infections, and lower rates of complications requiring intensive medical intervention.

Dr. Borelli described witnessing preventable medical catastrophes that could have been avoided with emergency department buprenorphine initiation: heart valve infections costing nearly $200,000 and often requiring open-heart surgery, kidney failure necessitating dialysis, spinal infections causing paralysis, and anoxic brain injuries requiring lifetime medical care. "It is devastating to see in a patient's medical chart that they sought treatment in the emergency department, were turned away without starting medication or a bridge prescription, and then went on to have a terrible medical outcome," she wrote.

The apparent contradiction between the Hospital Association's cost concerns and the evidence of significant savings likely reflects broader systemic issues. Emergency departments operate on thin margins and are reimbursed primarily for treating acute conditions rather than initiating ongoing care for chronic diseases. Even if buprenorphine initiation saves money system-wide, individual hospitals may view the immediate costs of providing medication and arranging follow-up as burdens not adequately compensated by current reimbursement structures.

Additionally, offering buprenorphine requires training emergency department staff, maintaining relationships with addiction treatment providers for referrals, and potentially navigating complex regulations around controlled substance prescribing. For hospitals already stretched by staffing shortages and financial pressures, mandating new services—even cost-effective ones—can feel like another obligation imposed without resources.

Proposed Amendments and Expansion

As SB 365 moves through the legislative process, advocates are pushing for several additions. The most significant would expand the medication options to include methadone alongside buprenorphine. While buprenorphine has become the dominant medication for office-based opioid treatment due to its safety profile and less restrictive regulations, methadone remains highly effective and preferred by some patients. Methadone is typically dispensed through specialized opioid treatment programs with daily supervised dosing for the first months of treatment, making it less practical for emergency department initiation, but emergency physicians could provide information, facilitate referrals, and potentially offer interim doses in some circumstances.

Another proposed amendment would extend the requirements beyond emergency departments to include patients admitted to medical or psychiatric hospital units. Someone admitted for an infection, injury, or psychiatric crisis who also has opioid use disorder would be offered medication-assisted treatment as part of their inpatient care rather than being expected to address their addiction separately after discharge. The logic mirrors the emergency department argument—medical crises create opportunities to engage patients who might not otherwise access addiction services.

The minimum seven-day bridge prescription proposal addresses a practical barrier. If a patient receives a three-day supply but the nearest available follow-up appointment is five days away, they face a dangerous gap when withdrawal returns and the risk of overdose increases. Ensuring prescriptions cover the full period until confirmed follow-up appointments protects patients during a vulnerable transition.

Broader Context: The Access Gap

Connecticut's legislative push reflects growing recognition that traditional addiction treatment models fail to reach many people who need help. Outpatient addiction clinics often have waiting lists, require insurance verification, operate limited hours, and may be geographically inaccessible to people without reliable transportation. Residential treatment programs can involve months-long waits and require patients to leave jobs and families. Emergency departments, by contrast, operate 24/7, must see anyone who walks through the door regardless of insurance, and are geographically distributed across the state.

The Substance Abuse and Mental Health Services Administration estimates that only about 20% of people with opioid use disorder receive any treatment in a given year. Of those who do seek help, many encounter barriers that delay or prevent access. Emergency departments represent a point in the healthcare system where people in crisis are already present, often at moments when motivation for change is highest. Failing to capitalize on these opportunities means losing chances to engage patients who may not return.

Research on emergency department-initiated buprenorphine consistently shows it increases treatment engagement. A seminal 2015 study published in JAMA found that patients who received buprenorphine in the emergency department plus a referral were significantly more likely to be engaged in addiction treatment at 30 days compared to those who received only referrals or brief interventions. The medication provides immediate relief from withdrawal, demonstrates that effective help exists, and creates a bridge to ongoing care rather than expecting patients to navigate complex treatment systems while actively struggling with addiction.

Implementation Challenges

If SB 365 becomes law, Connecticut emergency departments will face practical implementation challenges beyond cost concerns. Emergency physicians would need training on buprenorphine prescribing, recognizing opioid use disorder, assessing withdrawal severity, and navigating conversations about addiction treatment with patients who may be ambivalent or resistant. While the elimination of the federal X-waiver requirement in 2023 means any DEA-licensed practitioner can now prescribe buprenorphine without special certification, many emergency physicians still lack confidence and experience with the medication.

Hospitals would need to establish protocols for which patients should be offered buprenorphine, how to dose the medication, what bridge prescription duration to provide, and how to arrange follow-up care. Creating reliable referral networks with outpatient addiction providers, ensuring patients leave with confirmed appointments rather than vague suggestions to "follow up," and tracking outcomes to identify gaps all require infrastructure that many emergency departments currently lack.

Some emergency departments in Connecticut and other states have already implemented voluntary buprenorphine initiation programs and developed successful models. Hartford Hospital, for example, has offered emergency department-based buprenorphine since 2016 and created pathways to immediate outpatient follow-up. These existing programs could serve as templates for hospitals establishing new services to comply with SB 365.

Patient acceptance represents another variable. The legislation requires offering buprenorphine, not mandating that patients accept it. Some individuals may decline medication-assisted treatment due to stigma, misinformation about buprenorphine being "just substituting one drug for another," preferences for abstinence-based approaches, or simply not being ready for treatment despite seeking emergency care for other reasons. Respecting patient autonomy while ensuring informed decisions requires time and skill that emergency departments pressed by volume and acuity may struggle to provide.

National Precedent and Future Directions

Connecticut would not be breaking entirely new ground if SB 365 passes—several jurisdictions have implemented policies encouraging or requiring emergency department buprenorphine initiation. Massachusetts launched a statewide initiative in 2018 training emergency physicians in buprenorphine prescribing and creating referral networks. Rhode Island's coordinated approach to addressing opioid addiction included expanding emergency department medication access as a key component, contributing to the state achieving sustained reductions in overdose deaths.

However, Connecticut's approach would represent one of the more comprehensive legislative mandates, making buprenorphine access a requirement rather than an encouraged best practice. If successful, the model could influence other states considering similar legislation. Demonstrating that mandated emergency department buprenorphine is feasible, cost-effective, and improves outcomes would provide evidence for broader adoption. Conversely, if implementation proves difficult or hospitals successfully argue the mandate creates unsustainable burdens, it could dampen enthusiasm for replicating the approach elsewhere.

The legislation also touches on fundamental questions about the role of emergency medicine in addressing addiction. Emergency departments have traditionally focused on stabilizing acute conditions and connecting patients with ongoing care rather than initiating treatment for chronic diseases. Expanding this role to include addiction treatment represents a shift toward emergency medicine as a broader safety net, particularly for populations who access little other healthcare. Whether this expansion is appropriate, sustainable, and effective will shape not just Connecticut's opioid response but potentially how emergency departments nationwide conceptualize their responsibilities.

Dr. Borelli framed the issue starkly: "Not all patients will choose to take medication to treat their opioid use disorder, but not offering it is akin to denying antibiotics for sepsis." The comparison suggests that withholding evidence-based addiction treatment in emergency settings is not a neutral choice but an ethical failure equivalent to denying life-saving medication for other conditions.

What Comes Next

SB 365 currently awaits review by the Office of Legislative Research and Office of Fiscal Analysis, which will assess its legal implications and estimated costs. Following these reviews, the bill could move to committee votes and potentially floor votes in both chambers of the Connecticut General Assembly. The 2026 legislative session, which began February 4 and runs through May 6, provides a limited window for action.

Support from addiction medicine specialists, public health advocates, and families affected by the opioid crisis faces opposition from the state's hospital association and potentially from emergency physicians concerned about mandates expanding their responsibilities without adequate support. Whether the legislation advances, undergoes significant amendments, or stalls will depend on how lawmakers weigh the compelling evidence for emergency department buprenorphine against implementation concerns and institutional resistance.

For the thousands of Connecticut residents struggling with opioid addiction, the outcome matters profoundly. Emergency departments are often the only healthcare setting people in active addiction access regularly, if at all. Converting these crisis moments into treatment engagement opportunities could represent the difference between recovery and continued use, between survival and overdose. The question facing Connecticut legislators is not whether emergency department buprenorphine works—the evidence is clear—but whether the state will mandate that proven interventions reach people who desperately need them.